Omeros Corporation announced on April 10, 2025, the establishment of the Omeros Oncology Clinical Steering Committee to advance its OncotoX biologics program focused on acute myeloid leukemia (AML). AML is the most fatal form of leukemia, accounting for approximately 80 percent of acute leukemias in adults.
The OncotoX program for AML consists of proprietary targeted, engineered molecules designed to deliver a toxic payload within cancer cells, killing only dividing cancer cells while sparing normal cells. Preclinical studies in AML models have shown superior efficacy compared to current standard-of-care treatments and broad applicability across different genetic mutations.
The steering committee, comprised of distinguished clinical experts in AML, will assist Omeros with program development, clinical trial design, and interactions with institutional review boards. Omeros is initiating IND-enabling work for its OncotoX-AML therapeutic, aiming to address a high unmet need for oncologists and patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.